Financial Performance Highlights (Q1 FY27)

Income Statement:

  • Revenue from operations: INR 5,343 million (INR 534.3 crore), representing 52% year-on-year growth versus Q1 previous year.
  • Gross profit: INR 3,543 million versus INR 2,430 million in Q1 previous year (46% growth).
  • Pre-R&D EBITDA: INR 1,871 million (35.0% margin) versus 32.5% in Q1 previous year.
  • R&D expense: INR 580 million (10.9% of revenue) versus INR 355 million in Q1 previous year.
  • Operating EBITDA: INR 1,291 million (24.2% margin) versus INR 791 million (22.4% margin) in Q1 previous year, representing 63.2% growth.
  • PAT: INR 848 million versus INR 433 million in previous year (96% growth), including a one-off insurance claim for goods lost in transit.
  • EPS: INR 5.08
  • USD revenue: USD 55 million, up 32% year-on-year from USD 42 million

Balance Sheet (as of June 30, 2026):

  • Capital employed: INR 14,778 million (excluding cash and cash equivalents of INR 2,408 million)
  • Net working capital: 114 days versus 126 days as of March 31, 2026
  • ROCE: 36% for the quarter

Cash Flow Statement:

  • Operating cash flow before working capital change: INR 1,390 million
  • Net cash flow from operating activities: INR 285 million (impacted by delayed GST refunds expected to normalize in Q2)
  • Cash flow in investing activities: Primarily driven by acquisition of Arinna Lifesciences and capex

Business Performance and Operational Metrics

  • Revenue concentration: Top 5 products contributed 39% of revenue; top 10 products contributed 55%
  • Product approvals: Received 2 approvals in the quarter
  • Commercialization rate: 88%
  • Specialty portfolio contribution to gross profit: 36%
  • Gross margin: Increased sequentially by 140 bps to 67.7% despite increased input and freight costs due to geopolitical conditions

Strategic Updates and Guidance

EBITDA Margin Guidance: Revised upwards for FY27 to 23% from previous guidance of 22-23%, despite expected cost impacts from:

  • ESOP costs from new scheme
  • Arinna growth-related costs
  • Pre-revenue costs for new facilities in New Jersey and Pithampur

Manufacturing Facilities Update:

  • Pithampur Facility: FDA conducted unannounced inspection resulting in 483 with two procedural observations. Company filed appropriate response and received FDA approval on a regulatory filing. On track to ramp up commercial operations from Q1 calendar year 2027.
  • New Jersey Facility: Acquired via court-supervised bankruptcy process for USD 2.9 million. Facility received FDA inspection in May 2026 with Voluntary Action Classification (VAI) status. Located adjacent to distribution operations (AIMRX 3PL) and near US headquarters. Expected commercialization in calendar year 2027 after implementing quality management systems.

R&D Investment and Productivity

  • R&D spend guidance: INR 500 crores over nine quarters (FY26, FY27, and Q1 FY28)
  • Current spend: INR 251 crores completed in five quarters at rate of ~INR 60 crores per quarter
  • R&D productivity metric: 5.5x multiple (comparing incremental revenue to lagging R&D spend)
  • Historical R&D spend as percentage of revenue: 39.5% in FY22 (unlisted phase), normalized to 10-11%

Management Changes

  • Nitin Jajodia (current CFO) transitioning to Chief Commercial Officer role
  • Rohit joining as CFO designate, will assume CFO responsibilities after transition
  • Nitin joined in 2021 and played critical role in growing company from ~INR 400 crores revenue to INR 1,700 crores revenue

Acquisition Impact (Arinna Lifesciences)

  • Acquisition closed in April 2026
  • Revenue contribution: ~INR 12 crores in Q1 FY27
  • EBITDA contribution: Not material in Q1
  • Strategic focus: Growth identification and fixing growth levers in FY27, followed by beating IPM growth, with profitability focus in subsequent phases

Market Execution

Slide 22 data shows company ranked #1 in all six products showcased during IPO process, with market share improvements in four products despite competitive scenario.

Forward-looking Commentary

  • Q2 FY27 tracking strong for sequential USD revenue growth
  • Working capital expected to remain in range of 125-130 days
  • GST refund delays expected to normalize in Q2, improving cash flow
  • Strong revenue visibility for coming quarters
  • Specialty portfolio expected to continue growing